About Us

Our Mission

Our team consists of professional experts from different fields, including research scientists in disease biology, chemistry, pharmacology, and pharmacokinetics, as well as attending physician in neurology. Since 2006, we have successfully extracted a small molecule from a Chinese herb. Through optimization and different generations, we have successfully synthesized the compounds which have great potential to become new drug candidates for the treatment of neurodegenerative diseases. In aging societies, Dementia and Alzheimer’s disease (AD) are the most prominent neurodegenerative diseases. AD is a complex disease with substantial economic costs, and a burden on health service provision. While antibody-based therapies offer promising avenues in AD treatment, some challenges such as administration route, dosing regimen complexities, and side effects remain significant hurdles. Moreover, these treatments may not address the full spectrum of AD pathology or adequately restore cognitive function in advanced stages of the disease. The effective treatment of AD remains to be an unmet medical need and new drug targets are urgently needed.

Our team has been dedicated to studying the mechanism of the extracted compound and its analogues, based on strong and basic science research, for developing high-value therapeutic treatments. Neural Rejuvenation Team (NRT) was established since 2020 supported by BioTReC and Academia Sinica. We aim to develop novel therapies and solutions to address neurodegenerative diseases including Alzheimer's disease, Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS), as well as conditions such as muscle pain, sleep disorders and multiple sclerosis.